You are here

Article Text

Article menu

Download PDFPDF

Scientific letters
Long term persistence with statin treatment in daily medical practice
Free
  1. A K Mantel-Teeuwisse1,
  2. W G Goettsch2,
  3. O H Klungel1,
  4. A de Boer1,
  5. R M C Herings1,*
  1. 1Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands
  2. 2PHARMO Institute, Utrecht
  1. Correspondence to:
    A K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, PO Box 80082, 3508 TB Utrecht, The Netherlands; a.k.mantel-teeuwissepharm.uu.nl

http://dx.doi.org/10.1136/hrt.2003.026187

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Statin treatment is a safe and effective method of reducing cardiovascular events in both primary and secondary prevention.1,2 Persistence with statin use in trials is generally high. Analysis of the WOSCOPS (west of Scotland coronary prevention study) showed that the efficacy of pravastatin depends on compliance. Although long term persistence with statin treatment in elderly patients has been studied,3,4 little is known about long term persistence in the general population including all age categories and both primary and secondary prevention. The aim of this study was to assess long term persistence with statin use in the general Dutch population and to identify the determinants of failure to persist with these drugs.

    METHODS

    We used data from the PHARMO medical record linkage system including drug dispensing records from community pharmacies and hospital discharge records of 865 000 subjects in the Netherlands. Clustering pharmacies within PHARMO areas results in drug dispensing histories containing > 95% of all prescriptions dispensed to a particular patient.

    Persistence was assessed for all new users of statins (not receiving any statin for at least two years before being prescribed the first statin) during 1998–2002. Cerivastatin was withdrawn from the market and so patients receiving cerivastatin were excluded. Episodes of statin use were constructed for each patient. In cases of interruptions of < 45 days between …

    View Full Text